ClinicalTrials.gg
CompletedNCT03402984Updated Jan 18, 2018

Effect of Acotiamide on Gastric Motility and Satiation in Healthy Volunteers

An interventional study of Acotiamide and Placebo Oral Tablet in Healthy, sponsored by Universitaire Ziekenhuizen KU Leuven. Completed at 1 site in Belgium. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-18.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Apr 2017, registered Jan 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Introduction. Functional dyspepsia (FD) is a common chronic gastrointestinal disorder with a high socio-economic impact. Acotiamide, a new prokinetic agent, was shown to be efficacious in the treatment of FD, especially in the postprandial distress syndrome subgroup. To date, the exact mechanism of action of acotiamide is incompletely elucidated.

The aim of this study was to examine the effect of acotiamide on gastric motility, gastric emptying rate and gastrointestinal symptom perception in healthy participants in a randomized, placebo-controlled, cross-over study design. Participants were treated with acotiamide (100 mg t.i.d.) and placebo for 3 weeks, separated by a one-week wash-out period. At the end of each treatment period, gastric emptying and motility were assessed on two consecutive study days. During gastric motility assessment, epigastric symptom scores were collected at multiple time points.

02

Conditions studied

  • Healthy

Keywords

  • Gastric motility
  • Gastric emptying
03

In context

Lead sponsor

Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 963 studies on the registry; 267 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age: 18-60 years old.
  • Participant must provide witnessed written prior to any study procedures being performed.

Exclusion criteria

Exclusion criteria:

  • Age > 60 years old.
  • severely decreased kidney function.
  • severely decreased liver function.
  • severe heart disease, for example a history of irregular heartbeats, angina or heart attack.
  • severe lung disease.
  • severe psychiatric illness or neurological illness.
  • any gastrointestinal disease.
  • any dyspeptic symptoms.
  • pregnant or breastfeeding.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Acotiamide

    Acotiamide 100 mg t.i.d. for 3 weeks. Intake of medication 10 minutes before meal.

    Drug: Acotiamide

  • Placebo comparator
    Placebo

    Placebo tablets, t.i.d. for 3 weeks. Intake of placebo 10 minutes before meal.

    Drug: Placebo Oral Tablet

Interventions

  • Acotiamide treatment, 100 mg, t.i.d. for three week. Intake 10 minutes before meal.

  • DrugPlacebo Oral Tablet

    Placebo treatment, t.i.d. for three week. Intake 10 minutes before meal.

06

What researchers measure

Primary outcomes

  1. Gastric accommodation

    Relaxation of the stomach upon food intake

    Time frame: Gastric pressure was measured until 1 hour after the start of the liquid meal. Liquid meal started 10 minutes after medication/placebo intake

Secondary outcomes

  1. Gastric emptying

    Gastric emptying was assess by a 13C-octanoid acid breath test

    Time frame: Breath samples were collected before intake of medication/placebo and every 15 minutes until 4h after intake of 13C-octanoid acid

  2. Change in subjective gastrointestinal symptom scores measured by visual analogue scale of 100 mm

    Time frame: assessment by questionnaire (100 mm Visual Analogue Scale) every 5 minutes, up to 1 hour after administration of the liquid meal

07

Study locations

1 site
  • Jan Tack
    Leuven, 3000, Belgium
08

References and documents

Publications

  • Masuy I, Tack J, Verbeke K, Carbone F. Acotiamide affects antral motility, but has no effect on fundic motility, gastric emptying or symptom perception in healthy participants. Neurogastroenterol Motil. 2019 Apr;31(4):e13540. doi: 10.1111/nmo.13540. Epub 2019 Jan 20. PubMed 30663175 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in Jul 2017, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2018
First posted
Jan 18, 2018
StartActual
Apr 1, 2017
Primary completionActual
Jul 30, 2017
CompletionActual
Dec 4, 2017
Last update
Jan 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03402984
Responsible party
Sponsor
First posted
Jan 18, 2018
Start date
Apr 1, 2017
Primary completion
Jul 30, 2017
Completion
Dec 4, 2017
Last update
Jan 18, 2018

Study contacts

Jan Tack, PhD, MD
principal investigator · UZ Leuven / KU Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Z 338

Start the discussion